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The identiﬁcation of associations between interleukin-28B (IL-28B) variants and the spon-
taneous clearance of hepatitis C virus (HCV) raises the issues of causality and the net con-
tribution of host genetics to the trait. To estimate more precisely the net effect of IL-28B
genetic variation on HCV clearance, we optimized genotyping and compared the host con-
tributions in multiple- and single-source cohorts to control for viral and demographic
effects. The analysis included individuals with chronic or spontaneously cleared HCV
infections from a multiple-source cohort (n 5 389) and a single-source cohort (n 5 71).
We performed detailed genotyping in the coding region of IL-28B and searched for copy
number variations to identify the genetic variant or haplotype carrying the strongest asso-
ciation with viral clearance. This analysis was used to compare the effects of IL-28B varia-
tion in the two cohorts. Haplotypes characterized by carriage of the major alleles at IL-
28B single-nucleotide polymorphisms (SNPs) were highly overrepresented in individuals
with spontaneous clearance versus those with chronic HCV infections (66.1% versus
38.6%, P 5 6 3 10
29). The odds ratios for clearance were 2.1 [95% conﬁdence interval
(CI) 5 1.6-3.0] and 3.9 (95% CI 5 1.5-10.2) in the multiple- and single-source cohorts,
respectively. Protective haplotypes were in perfect linkage (r
2 5 1.0) with a nonsynony-
mous coding variant (rs8103142). Copy number variants were not detected. Conclusion:
We identiﬁed IL-28B haplotypes highly predictive of spontaneous HCV clearance. The
high linkage disequilibrium between IL-28B SNPs indicates that association studies need
to be complemented by functional experiments to identify single causal variants. The point
estimate for the genetic effect was higher in the single-source cohort, which was used to
effectively control for viral diversity, sex, and coinfections and, therefore, offered a precise
estimate of the net host genetic contribution. (HEPATOLOGY 2011;53:1446-1454)
H
epatitis C virus (HCV) infections resolve
spontaneously in 30% to 50% of cases.
1 Sex,
ethnicity, jaundice, and coinfections with
human immunodeﬁciency virus (HIV) and hepatitis B
virus affect spontaneous HCV clearance.
2 Recently,
genetic variation in the interleukin-28B gene (IL-28B)
was shown to strongly predict viral clearance,
3-5 with
similar effects found in HCV-monoinfected and HIV/
HCV-coinfected individuals.
3,4 The two strongest
genetic predictors for spontaneous HCV clearance, the
rs12979860 C allele and the rs8099917 T allele, are
located 3 and 8 kb upstream of the IL-28B gene,
respectively.
3 However, at this stage, it is uncertain
whether these polymorphisms play a causal role or are
merely tagging one or more unknown causal variants.
To identify the functional variant tagged by the
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1446associated single-nucleotide polymorphism (SNP), we
performed comprehensive genetic mapping of the
region to identify the most plausible causal SNP for
spontaneous HCV clearance.
HCV-speciﬁc immune responses inﬂuence clinical
outcomes and strongly depend on the viral geno-
type.
2,6 Ideally, the identiﬁcation of the optimal host
genetic marker for spontaneous HCV clearance would
control for this viral variable. However, because the ge-
notype of the infecting virus is unknown in most
infected individuals once they have cleared the virus,
an assessment of the relative contribution of host
genetics versus viral genetics to HCV clearance is
rarely possible. Single-source outbreaks provide a
unique opportunity for studying the net host genetic
effects independently of the viral genotype and diver-
sity. Therefore, we assessed the inﬂuence of IL-28B
variants on spontaneous HCV clearance in a cohort of
women infected by an identical HCV genotype 1b
strain through contaminated anti-D immunoglobulins,
and we compared the genetic effects in this single-
source source and a multiple-source cohort.
The aim of this study was to improve the prediction
of spontaneous HCV clearance through (1) the optimi-
zation of IL-28B genotyping and (2) the estimation of
the net host genetic effects with a single-source outbreak.
Patients and Methods
Study Population. The multiple-source cohort
included 389 randomly selected HIV/HCV-coinfected
individuals (200 with spontaneous HCV clearance and
189 with chronic hepatitis C). The study participants
were recruited through the Swiss HIV Cohort Study.
The cohort included HIV-infected individuals coin-
fected with diverse HCV genotypes and was heteroge-
neous with respect to sex, viral coinfections, and age
(Supporting Table 1).
Individuals from the single-source outbreak were
part of a cohort of 704 women infected with HCV ge-
notype 1b through contaminated anti-D immunoglo-
bulins as described elsewhere.
7 Infections occurred
between May 1977 and November 1978 in Ireland.
From this cohort, we included those currently attend-
ing routine clinical follow-up; 27 experienced sponta-
neous HCV clearance, and 44 had chronic hepatitis C.
All study participants gave informed consent, which
included genetic testing.
Spontaneous HCV clearance was deﬁned as HCV
seropositivity (determined with an enzyme-linked im-
munosorbent assay and conﬁrmed by immunoblotting)
and negative HCV RNA ﬁndings by quantitative or
qualitative assays more than 12 months after HCV
seropositivity. Chronic hepatitis C was deﬁned as HCV
seropositivity and detectable HCV RNA more than 12
months after HCV seropositivity. Demographic charac-
teristics are shown in Supporting Table 1.
Genotyping and Copy Number Variation (CNV)
Determination. Because our previous genome-wide
association study clearly indicated that the association
signal maps to IL-28B, we further explored this gene
in more detail. On the basis of our previous work on
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3 the genotyping
of four candidate causal SNPs (rs4803219,
rs28416813, rs8103142, and rs4803217) was per-
formed by TaqMan allelic discrimination (ABI-Prism
7000 SDS software, Applied Biosystems) with custom
Assays-on-Demand products from Applied Biosystems;
this was preceded by a pre-ampliﬁcation step. Primers
and probes are shown in Supporting Table 2. In addi-
tion, the tag SNP rs12979860 was assessed with a cus-
tom TaqMan assay designed by Ge et al.,
8 and the tag
SNP rs8099917 was genotyped with an Assays-on-
Demand product provided by Applied Biosystems
(C__11710096_10). Haplotype inference was per-
formed with Phase 2.1 software (University of Wash-
ington, Seattle, WA).
An analysis of CNVs (deletions, insertions, and
inversions) was initiated through an inspection of the
structural variation at the IL-28B locus and 1 Mb (1
million nucleotides) upstream and downstream of the
gene in chromosome 19 (as captured in the 1000
Genomes Project; go to http://www.1000genomes.org
for the March 2010 data release).
9 The analysis
included calls from both pilot 1 [179 samples
sequenced with low-pass shotgun (2-6 ) coverage] and
pilot 2 [6 individuals with high (>30 ) coverage] of
the 1000 Genomes Project. CNV calls from the 1000
Genomes Project are reported as validated, unvali-
dated, and invalidated on the basis of a number of
algorithms, experimental data, and replication across
various samples and populations.
The presence of CNVs was then experimentally
assessed by quantitative real-time polymerase chain
reaction (PCR); the primers and probes are shown in
Supporting Table 2. The CNV assessment with real-
time PCR included a clone containing one copy of IL-
28B and the housekeeping gene hydroxymethylbilane
synthase as a control (Supporting Table 2). Because
the quantitative PCR approach allowed the detection
of CNVs only in a limited region of the gene (set by
the location of the chosen primers), we further assessed
potential CNVs with primer combinations that would
amplify a PCR product only in the presence of CNVs
(Supporting Fig. 1). The targeted PCR across potential
CNVs was internally controlled by the identiﬁcation
of the expected ampliﬁcation fragment or larger/
shorter fragments.
Statistics. Genetic associations were assessed by
logistic regression. The analyses were adjusted for cova-
riates signiﬁcantly associated with spontaneous HCV
clearance in univariate analyses. Haplotype analyses
were performed with the haplologit command in the
Stata software package (version 10.0). This analysis
included haplotypes exceeding a frequency of 2/N (the
default threshold). The estimates of haplotype effects
were adjusted for signiﬁcant covariates in logistic
regression models.
Results
Genotyping Candidate Causal Variants. Our pre-
vious genome-wide association study identiﬁed
rs8099917 as the strongest predictor of spontaneous
HCV clearance.
3 This variant is located within a
genomic block encompassing the IL-28B gene and is,
therefore, susceptible to reﬂecting the signal resulting
from a functional variant in IL-28B. To identify the
potentially causal variant tagged by rs8099917, IL-28B
had been previously resequenced in 41 HIV/HCV-
coinfected individuals with the four extreme genotype/
phenotype combinations: chronic or spontaneously
cleared hepatitis C and homozygosity for the protec-
tive or risk alleles.
3 Candidate causal SNP selection
was based on location, frequency among the main
haplotype families, and linkage disequilibrium.
3 This
approach led to the prioritization of four SNPs as
prime candidates for causality (Fig. 1A). These four
SNPs were genotyped along with the two tagging
SNPs that were most strongly associated with sponta-
neous HCV clearance in previous studies (rs8099917
and rs12979860
3,4). Twelve distinct haplotypes could
then be derived from the six genotyped SNPs, as
shown in Fig. 1B. The haplotypes were further catego-
rized according to the classiﬁcation used in our previ-
ous study into two main families (Fig. 1B). Type I
haplotypes were characterized by the presence of the
common allele for all candidate SNPs (Fig. 1B).
Genotyping Assay Optimization. Because of the
high homology between the IL-28B and IL-28A
sequences (96% amino acid identity
10), we ﬁrst per-
formed a pre-ampliﬁcation step in order to selectively
genotype IL-28B polymorphisms in the TaqMan
assays. The four candidate SNPs were then genotyped
from the pre-ampliﬁed product. However, we observed
discrepancies in up to 19.5% of cases for rs8103142
between the TaqMan results and the previous rese-
quencing results.
3 Discrepancies were present for vari-
ous pre-ampliﬁcation primer combinations (marked
with dashed lines in Fig. 2), with more frequent
homozygosity found with the TaqMan assay; this sug-
gested the preferential ampliﬁcation of only one allele
in some individuals. Further optimization of the pre-
ampliﬁcation step identiﬁed primer combinations that
correctly identiﬁed all genotypes (marked with solid
lines in Fig. 2). Primer combinations that included a
1448 DI IULIO ET AL. HEPATOLOGY, May 2011Fig. 1. IL-28B genotyping and haplotype inference. (A) Two tagging SNPs (rs8099917 and rs12979860) and four candidate causal SNPs in
IL-28B were genotyped in all study participants. Boxes 1 to 5 denote exons. (B) Haplotype inference identiﬁed 12 distinct haplotypes divided
into two main families (types I and II). Arrowheads indicate the presence of the minor allele.
Fig. 2. Primer pair optimization for the pre-ampliﬁcation step. Because discordant results were obtained by genotyping and resequencing, sev-
eral primer combinations were tested for the pre-ampliﬁcation step preceding the genotyping. The arrows show the different PCR products ampli-
ﬁed for the pre-ampliﬁcation step. Arrows with dashed lines indicate discordant results for a given SNP (heterozygous by resequencing and
homozygous by the TaqMan assay), whereas arrows with solid lines indicate concordant results for a given SNP (heterozygous by both resequenc-
ing and TaqMan assay). A primer combination containing a forward primer located upstream of position g.-520G yielded discordant results in up
to 19.5% of the individuals (for rs8103142). The red triangles show the location of the four genotyped SNPs.
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concordant results. Primers and probes that were used
in the optimized genotyping assay are listed in Sup-
porting Table 2.
CNVs. To further characterize the genetic region,
we assessed whether CNVs (deletions, insertions, and
inversions) exist in the IL-28B region. An analysis of
pilot 1 data from the 1000 Genomes Project identiﬁed
113 possible instances of CNVs in the window of 2
Mb around the IL-28B locus (Fig. 3A). These corre-
spond to 107 deletions and 6 insertions; 43 of these
have been validated, and validation is pending for 70.
An analysis of the pilot 2 data identiﬁed 110 possible
instances of CNVs; these correspond to 106 deletions,
3 duplications, and 1 inversion, and 48 have been vali-
dated. Validation is pending for 53, and 9 have been
invalidated (Fig. 3B). However, none of the reported
CNVs directly involve IL-28B, with the exception of
an inversion (yet to be validated) reported in one indi-
vidual in the IL-28B–IL-28A intergenic region (Fig.
3C,D).
We could not identify any CNV with quantitative
real-time PCR using primers amplifying a region of
121 bp that spanned exon 5 and the 30-untranslated
region (data not shown). The customized PCR
described in Supporting Fig. 1A revealed potential
gene duplications; however, these were entirely
explained by artifactual formation of gene copies due
to PCR-induced recombination of repetitive regions in
the IL-28B region (Supporting Fig. 1B).
11
Fig. 3. CNVs at the IL-28B locus. (A,B) CNV data from the 1000 Genomes Project (pilots 1 and 2) for 1 Mb upstream and downstream of
the IL-28B locus (black, vertical lines) in chromosome 19. The y axis and the horizontal color lines represent individual observations of possible CNVs
(orange, not yet conﬁrmed; red, refuted/invalidated; green, conﬁrmed/validated). (C,D) Close-ups of the locus. The gray, vertical lines indicate the chro-
mosomal locations of IL-28B, IL-28A,a n dIL-29.
1450 DI IULIO ET AL. HEPATOLOGY, May 2011Predictive Value of Candidate SNPs for Spontane-
ous HCV Clearance in the Multiple-Source
Cohort. Using the optimized pre-ampliﬁcation step,
we genotyped the four candidate causal variants in the
entire cohort. All SNPs were highly associated with
spontaneous HCV clearance and had a stronger effect
in comparison with the tagging SNP rs8099917 iden-
tiﬁed in our previous genome-wide association study
3
(Table 1). Using nested regression models, we observed
that rs8099917 was not signiﬁcantly associated after an
adjustment for candidate SNPs (P > 0.1 for all com-
parisons), whereas the candidate causal variants
remained signiﬁcantly associated with spontaneous
HCV clearance after we accounted for rs8099917 (P
< 0.001 for all comparisons). The linkage disequili-
brium between rs8099917 and the candidate causal
variants was moderate (r
2   0.4; Fig. 4), whereas the
other tag SNP, rs12979860,
8 was highly linked to the
candidate variants (r
2   0.85, Fig. 4).
Predictive Value of Candidate SNPs for Spontane-
ous HCV Clearance in the Single-Source Cohort. We
next investigated the net host genetic contribution to
spontaneous HCV clearance in the single-source
cohort. Again, all genotyped SNPs were signiﬁcantly
associated with spontaneous HCV clearance. The can-
didate causal SNPs were more strongly associated than
the tagging SNP rs8099917 and were in perfect link-
age disequilibrium with rs12979860, except for
rs4803219 (r
2 ¼ 0.93; Table 2).
IL-28B Haplotypes and Spontaneous HCV Clear-
ance. We next examined the association of IL-28B
haplotypes with spontaneous HCV clearance. In both
cohorts, haplotypes characterized by carriage of the
major alleles at IL-28B candidate SNPs had the strong-
est association with clearance (Table 3). These type I
haplotypes (Fig. 1B) were clearly enriched in individu-
als with spontaneous HCV clearance, and there was a
greater association in the single-source cohort (Fig. 5).
Homozygosity for type I haplotypes was highly linked
to the rs12979860 CC genotype (r
2 ¼ 0.97).
Discussion
Genetic variation in IL-28B is the strongest known
genetic predictor of natural and treatment-induced
clearance of HCV infection. Although there is over-
whelming evidence for the association of SNPs with
HCV infection outcomes, the causal genetic variant
has not been identiﬁed yet. Using a comprehensive
and optimized genetic analysis of IL-28B, we evaluated
SNPs in the coding, promoter, and 30-untranslated
regions of the gene that could represent causal variants.
Haplotypes characterized by carriage of the major al-
leles at the IL-28B candidate SNPs (type I haplotypes)
were highly overrepresented in individuals with
Table 1. Association Between the IL-28B Genotype and HCV Clearance (Multiple-Source Cohort)
SNP
Minor Allele Frequency
Odds Ratio for Spontaneous Clearance
(Noncarrier Versus Carrier) P Value* HCV Clearance HCV Chronicity
Tagging SNPs rs8099917 0.12 0.23 2.5 (1.6-3.9) 9   10
 5
rs12979860 0.20 0.36 3.0 (1.9-4.5) 5   10
 7
Candidate causal SNPs rs4803219 0.19 0.32 2.6 (1.7-3.8) 1   10
 5
rs28416813 0.20 0.35 3.0 (1.9-4.5) 5   10
 7
rs8103142 0.21 0.36 3.0 (2.0-4.6) 2   10
 7
rs4803217 0.20 0.35 3.0 (2.0-4.6) 3   10
 7
*P values were adjusted for sex andcoinfectionwithhepatitis B.
Fig. 4. Linkage disequilibrium plot for the multiple-source cohort.
The linkage disequilibrium between the four candidate causal SNPs
(rs4803219, rs28416813, rs8103142, and rs4803217) and the two
previously identiﬁed tagging SNPs is shown.
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HCV infections. Homozygosity for the rs12979860 C
allele (CC genotype) tagged (r
2 ¼ 0.97) homozygosity
for the protective type I haplotypes. Protective type I
haplotypes were in perfect linkage (r
2 ¼ 1.0) with a
nonsynonymous coding variant (rs8103142) that has
also been highly associated with treatment response.
8,12
Although rs8099917 was only moderately linked to the
SNPs in the IL-28B gene, there was a high linkage of
rs12979860 with the four candidate causal SNPs in
both cohorts. The candidate causal SNPs and haplo-
types were, therefore, better tagged by rs12979860
than rs8099917. Furthermore, rs12979860 and the
candidate causal SNPs remained signiﬁcantly associated
with HCV clearance after we accounted for rs8099917.
In contrast, rs8099917 was not signiﬁcantly associated
after an adjustment for candidate causal SNPs. There-
fore, we conclude that candidate causal SNPs and
rs12979860 are better predictors of spontaneous HCV
clearance than rs8099917. The candidate SNPs are in
very high linkage disequilibrium (Fig. 4). This indicates
that association studies are not sufﬁcient to identify the
causal SNPs, at least in Caucasians. Functional studies
are needed to deﬁne which variants ultimately inﬂuence
the control of HCV infection.
Even if protective IL-28B genotypes were clearly
enriched in individuals with spontaneous HCV clear-
ance in both cohorts, the point estimate of the odds
ratio was approximately 2-fold higher in the single-
source cohort. Women homozygous for the protective
type I haplotypes were approximately 4 times more
likely to spontaneously clear their HCV infection in
comparison with women carrying at least one type II
haplotype. Because of the inherent control of clinical,
demographic, and viral factors in the single-source
cohort, this point estimate represents an optimal
assessment of the net host genetic contribution. This
ﬁnding is in line with a very recent report by Tillmann
and colleagues,
13 who found a strong association
between the rs12979860 CC genotype and spontane-
ous HCV clearance in a German single-source cohort.
In the multiple-source cohort, the effects of IL-28B
haplotypes on spontaneous HCV clearance were simi-
lar in men [odds ratio ¼ 2.3, 95% conﬁdence interval
(CI) ¼ 1.5-4.2] and women (odds ratio ¼ 2.3, 95%
CI ¼ 1.5-3.6). Furthermore, IL-28B has very similar
effects on spontaneous HCV clearance in HIV/HCV-
coinfected and HCV-monoinfected individuals.
3-5
Although the inherent heterogeneity between the two
cohorts makes it difﬁcult to compare predictors of
spontaneous HCV clearance, it is unlikely that the
larger effect in the single-source cohort can be
explained entirely by the different distributions of sex
and coinfection with HIV. The inﬂuence of viral geno-
types on spontaneous HCV clearance rates is poorly
understood. This is mainly due to the paucity of acute
hepatitis C cohorts in which the viral genotype can be
assessed in individuals who spontaneously clear their
Table 3. Association Between the IL-28B Haplotypes and HCV Clearance
IL-28B SNP in the Promoter/Coding Region and 30-Untranslated Region* Multiple-Source Cohort Single-Source Cohort
rs4803219 (C>T) rs28416813 (C>G) rs8103142 (T>C) rs4803217 (C>A) Odds Ratio (95% CI)y P Value Odds Ratio (95% CI)y P Value
0 0 0 0 2.1 (1.6-3.0) 2   10
 6 3.9 (1.5-10.2) 0.005
0 0 1 0 1.4 (0.2-8.6) 0.7 —‡ —‡
0 1 1 1 0.3 (0.1-0.9) 0.04 —‡ —‡
1 1 1 1 0.5 (0.3-0.7) 2   10
 5 0.3 (0.09-0.7) 0.006
*0 ¼ major allele; 1 ¼ minor allele.
†Odds ratios were adjusted for IL-28B haplotypes, sex, andcoinfectionwithhepatitis B.
‡The numbers were too small for odds ratio calculations.
Table 2. Association Between the IL-28B Genotype and HCV Clearance (Single-Source Cohort)
SNP
Minor Allele Frequency
Odds Ratio for Spontaneous Clearance
(Noncarrier Versus Carrier) P Value* HCV Clearance HCV Chronicity
Tagging SNPs rs8099917 0.08 0.20 3.3 (1.0-11.2) 0.05
rs12979860† 0.13 0.34 4.1 (1.4-11.8) 0.008
Candidate causal SNPs rs4803219 0.11 0.33 4.6 (1.6-13.6) 0.005
rs28416813† 0.13 0.34 4.1 (1.4-11.8) 0.008
rs8103142† 0.13 0.34 4.1 (1.4-11.8) 0.008
rs4803217† 0.13 0.34 4.1 (1.4-11.8) 0.008
*P values were adjusted for sex andcoinfectionwithhepatitis B.
†In perfect linkage disequilibrium in this cohort.
1452 DI IULIO ET AL. HEPATOLOGY, May 2011infections. The limited overlap of T cell responses
between HCV genotypes
6 suggests that the viral geno-
type inﬂuences the host immune response to HCV. It
is, therefore, not surprising that the effect of IL-28B
variants was larger in the single-source cohort, which
was used to control for viral effects. Although the dif-
ference in the odds ratios between the single- and mul-
tiple-source cohorts was not statistically signiﬁcant
with overlapping CIs, it is interesting to note that the
highest odds ratios for spontaneous HCV clearance
were observed in the Irish and German single-source
cohorts. This underscores the advantages of single-
source cohorts for genetic association studies of infec-
tious diseases because these cohorts allow the net host
genetic determinants to be assessed independently of
pathogen-associated variability.
Our study also identiﬁed substantial technical com-
plexity in the genetic analysis of the IL-28B locus.
First, the high homology between IL-28A and IL-28B
requires pre-ampliﬁcation of IL-28B before the geno-
typing of SNPs in the promoter, coding, and 30-
untranslated regions of IL-28B by TaqMan in order to
avoid unspeciﬁc ampliﬁcation of IL-28A, which can
result in erroneous genotypes. Second, the pre-ampliﬁ-
cation step needs optimized primer combinations;
upstream of position g.-520G, the forward primer
does not reliably amplify both alleles, and this can
result in erroneous genotype distributions for SNPs in
the promoter, coding, and 30-untranslated regions of
IL-28B. Tagging SNPs can be genotyped reliably with-
out a pre-ampliﬁcation step because these are not
located in a region with high homology with IL-28A.
Therefore, our ﬁndings do not alter the conclusions of
previous reports on the impact of the tagging SNPs
rs12979860 and rs8099917 on the control of HCV
infection. Third, repetitive homology regions can arti-
factually simulate CNVs. The study also proceeded to
an analysis of CNVs, which were a consideration
because of the close proximity of the IL-28B and IL-
28A paralogs. The analysis of CNVs captured in the
1000 Genomes Project identiﬁed several validated
CNVs near IL-28B; however, none of these encom-
passed the IL-28B gene. Furthermore, neither real-time
nor targeted PCR identiﬁed CNVs. It is, therefore,
unlikely that CNVs play a role in the strong inﬂuence
of IL-28B variation on HCV infection outcomes.
Completion of the 1000 Genomes Project, which will
yield many more samples sequenced with high cover-
age, may lead to a better understanding of the genetic
structure around the IL-28B locus.
Our study has conﬁrmed and extended previous
observations. We have conﬁrmed the high linkage of
rs12979860 to candidate causal IL-28B SNPs observed
in the Individualized Dosing Efﬁcacy Versus Flat Dos-
ing to Assess Optimal Pegylated Interferon Therapy
(IDEAL) cohort,
8 and we have additionally described
the inﬂuence of these variants on spontaneous HCV
clearance. Furthermore, we have demonstrated that the
Fig. 5. IL-28B haplotypes and spontaneous HCV clearance in the multiple- and single-source cohorts. The odds ratios were adjusted for IL-
28B haplotypes, sex, and coinfection with hepatitis B. Abbreviation: HBsAg, hepatitis B surface antigen.
HEPATOLOGY, Vol. 53, No. 5, 2011 DI IULIO ET AL. 1453rs12979860 CC genotype tags homozygosity for pro-
tective type I haplotypes that are characterized by car-
riage of major alleles of IL-28B candidate causal SNPs.
We have also described the substantial complexity of
the genetic analysis of the IL-28B locus, and we have
presented a new approach to identifying samples with
particular IL-28B genotypes for functional studies.
Our study has also conﬁrmed the strong effect of IL-
28B variation in the German single-source cohort,
13
has extended the genetic assessment, and has provided
comparative estimates of multiple- and single-source
cohorts and thereby effectively deﬁned the net host
contribution to the phenotype. Finally, previous studies
that assessed the potential role of CNVs in HCV
infection outcomes
8 relied on the information pro-
vided by HapMap (see http://hapmap.ncbi.nlm.nih.-
gov). Because this approach provides relatively poor
discrimination for detecting CNVs, we performed an
extensive screening of the region with the 1000
Genomes Project data and real-time and targeted
PCR. These studies and the current work jointly repre-
sent a deﬁnitive assessment of genetic variation at the
IL-28B locus and indicate the limits of genetic
approaches to the understanding of the mechanism of
action of IL-28B.
In conclusion, SNPs located in the promoter, cod-
ing, and 30-untranslated regions of IL-28B are highly
associated with spontaneous HCV clearance. These
SNPs are prime candidates for functional assessment.
The method described here can be useful to identify
samples with particular IL-28B genotypes for func-
tional studies. We also have conﬁrmed that for large-
scale studies, rs12979860 genotyping is a reliable
method for predicting the presence or absence of the
putative causal haplotypes in IL-28B associated with
spontaneous HCV clearance. The striking association
of IL-28B genotypes with spontaneous HCV clearance
in a single-source cohort underscores the role of host
genetic variation in the control of HCV infection,
which is independent of viral effects.
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